loading
Schlusskurs vom Vortag:
$21.48
Offen:
$21.37
24-Stunden-Volumen:
50,806
Relative Volume:
0.38
Marktkapitalisierung:
$226.57M
Einnahmen:
$56.54M
Nettoeinkommen (Verlust:
$-30.70M
KGV:
-55.23
EPS:
-0.39
Netto-Cashflow:
$-31.05M
1W Leistung:
+10.80%
1M Leistung:
-2.22%
6M Leistung:
+70.95%
1J Leistung:
+65.69%
1-Tages-Spanne:
Value
$20.95
$22.06
1-Wochen-Bereich:
Value
$19.18
$22.82
52-Wochen-Spanne:
Value
$10.14
$28.42

Cidara Therapeutics Inc Stock (CDTX) Company Profile

Name
Firmenname
Cidara Therapeutics Inc
Name
Telefon
858-752-6170
Name
Adresse
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Name
Mitarbeiter
73
Name
Twitter
@CidaraThera
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
CDTX's Discussions on Twitter

Vergleichen Sie CDTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CDTX
Cidara Therapeutics Inc
21.54 226.57M 56.54M -30.70M -31.05M -0.39
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-12 Eingeleitet Citizens JMP Mkt Outperform
2025-01-27 Fortgesetzt Cantor Fitzgerald Overweight
2024-12-13 Eingeleitet RBC Capital Mkts Outperform
2024-11-08 Eingeleitet Guggenheim Buy
2024-08-14 Hochstufung H.C. Wainwright Neutral → Buy
2021-12-03 Fortgesetzt H.C. Wainwright Buy
2021-09-22 Hochstufung WBB Securities Buy → Strong Buy
2021-03-04 Eingeleitet Aegis Capital Buy
2019-09-04 Hochstufung Wedbush Neutral → Outperform
2018-07-26 Eingeleitet Citigroup Buy
2017-04-21 Eingeleitet Raymond James Strong Buy
2017-04-17 Bestätigt H.C. Wainwright Buy
2017-04-12 Eingeleitet Ladenburg Thalmann Buy
2017-04-11 Fortgesetzt Wedbush Outperform
2017-02-22 Bestätigt H.C. Wainwright Buy
2017-02-22 Hochstufung WBB Securities Sell → Hold
2016-12-21 Fortgesetzt Leerink Partners Outperform
2016-12-19 Eingeleitet H.C. Wainwright Buy
2016-09-23 Herabstufung WBB Securities Hold → Sell
2015-10-09 Hochstufung WBB Securities Sell → Hold
2015-05-11 Eingeleitet Jefferies Buy
2015-05-11 Eingeleitet Leerink Partners Outperform
2015-05-11 Eingeleitet Needham Buy
2015-05-11 Eingeleitet Wedbush Outperform
2015-04-23 Eingeleitet WBB Securities Sell
Alle ansehen

Cidara Therapeutics Inc Aktie (CDTX) Neueste Nachrichten

pulisher
Apr 24, 2025

Cidara Therapeutics to Report First Quarter 2025 Financial Results on May 8, 2025 - Nasdaq

Apr 24, 2025
pulisher
Apr 24, 2025

Cidara Therapeutics to Report First Quarter 2025 Financial - GlobeNewswire

Apr 24, 2025
pulisher
Apr 20, 2025

(CDTX) Trading Signals - news.stocktradersdaily.com

Apr 20, 2025
pulisher
Apr 16, 2025

Cidara Therapeutics (NASDAQ:CDTX) Upgraded to “Sell” at StockNews.com - Defense World

Apr 16, 2025
pulisher
Apr 12, 2025

Needham & Company LLC Reaffirms “Buy” Rating for Cidara Therapeutics (NASDAQ:CDTX) - Defense World

Apr 12, 2025
pulisher
Apr 07, 2025

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of “Buy” from Analysts - Defense World

Apr 07, 2025
pulisher
Apr 05, 2025

Cidara Therapeutics (NASDAQ:CDTX) Upgraded by StockNews.com to Sell Rating - Defense World

Apr 05, 2025
pulisher
Apr 04, 2025

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Significant Increase in Short Interest - Defense World

Apr 04, 2025
pulisher
Apr 02, 2025

Cidara Therapeutics (NASDAQ:CDTX) Shares Pass Above 50 Day Moving Average – Time to Sell? - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

New Executive Joins Cidara Therapeutics with $580K+ Stock Compensation Package - Stock Titan

Apr 01, 2025
pulisher
Apr 01, 2025

Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Cidara Therapeutics Unveils Latest Innovations at Elite Needham Healthcare Conference - Stock Titan

Apr 01, 2025
pulisher
Mar 25, 2025

(CDTX) Investment Analysis - news.stocktradersdaily.com

Mar 25, 2025
pulisher
Mar 24, 2025

Elicio Therapeutics Hires CFO From Cidara Therapeutics - MarketWatch

Mar 24, 2025
pulisher
Mar 24, 2025

Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer - GlobeNewswire

Mar 24, 2025
pulisher
Mar 21, 2025

Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics (CDTX): Here's What You Should Know - MSN

Mar 21, 2025
pulisher
Mar 19, 2025

Cidara Therapeutics to Participate in World Health - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

Cidara Therapeutics to present on CD388 at ICAR 2025 - Yahoo Finance

Mar 19, 2025
pulisher
Mar 19, 2025

Cidara's Breakthrough H5N1 Flu Drug Takes Center Stage at WHO Emergency Preparedness Meeting - StockTitan

Mar 19, 2025
pulisher
Mar 19, 2025

Short Interest in Cidara Therapeutics, Inc. (NASDAQ:CDTX) Increases By 30.7% - Defense World

Mar 19, 2025
pulisher
Mar 18, 2025

Cidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025 - The Manila Times

Mar 18, 2025
pulisher
Mar 18, 2025

Cidara Therapeutics Announces Two Presentations on CD388 in - GlobeNewswire

Mar 18, 2025
pulisher
Mar 18, 2025

Major Milestone: Cidara's Novel Flu Prevention Drug Completes Massive 5,000-Patient Trial - StockTitan

Mar 18, 2025
pulisher
Mar 17, 2025

Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology - GlobeNewswire

Mar 17, 2025
pulisher
Mar 17, 2025

Revolutionary Universal Flu Drug Shows Promise Against All Strains, Including Bird Flu - StockTitan

Mar 17, 2025
pulisher
Mar 16, 2025

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives $39.14 Average Target Price from Analysts - Defense World

Mar 16, 2025
pulisher
Mar 14, 2025

(CDTX) Long Term Investment Analysis - Stock Traders Daily

Mar 14, 2025
pulisher
Mar 14, 2025

Citizens Jmp Begins Coverage on Cidara Therapeutics (NASDAQ:CDTX) - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Cidara therapeutics COO Shane Ward sells shares worth $36,542 By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

Cidara therapeutics chief scientific officer sells shares worth $38,939 By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

Cidara therapeutics COO Shane Ward sells shares worth $36,542 - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Cidara therapeutics chief scientific officer sells shares worth $38,939 - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Cidara Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

HC Wainwright Issues Negative Estimate for CDTX Earnings - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Citizens Capital Markets Initiates Coverage of Cidara Therapeutics (CDTX) with Market Outperform Recommendation - Nasdaq

Mar 12, 2025
pulisher
Mar 12, 2025

Cidara stock gains on Citizens' bullish view (CDTX:NASDAQ) - Seeking Alpha

Mar 12, 2025
pulisher
Mar 12, 2025

Cidara Therapeutics initiated with an Outperform at Citizens JMP - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Cidara stock gains on JMP analyst’s upbeat outlook By Investing.com - Investing.com Canada

Mar 12, 2025
pulisher
Mar 12, 2025

FY2029 Earnings Forecast for CDTX Issued By HC Wainwright - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Buy Rating for Cidara Therapeutics: Promising Potential of CD388 in Influenza Prevention - TipRanks

Mar 12, 2025
pulisher
Mar 11, 2025

HC Wainwright Issues Positive Forecast for Cidara Therapeutics (NASDAQ:CDTX) Stock Price - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

Cidara stock price target raised to $35 at H.C. Wainwright By Investing.com - Investing.com Canada

Mar 10, 2025
pulisher
Mar 10, 2025

Cidara Therapeutics price target raised to $35 from $24 at H.C. Wainwright - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Ed Arce’s Buy Rating for Cidara Therapeutics Driven by Accelerated CD388 Program and Promising Phase 2b NAVIGATE Study Developments - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Head-To-Head Analysis: Cidara Therapeutics (NASDAQ:CDTX) vs. Neumora Therapeutics (NASDAQ:NMRA) - Defense World

Mar 10, 2025

Finanzdaten der Cidara Therapeutics Inc-Aktie (CDTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Kapitalisierung:     |  Volumen (24h):